Impact of Biologics on Nasal Symptoms in Severe Asthmatics: Findings From the PRISM Study.

ABSTRACT:

Purpose

The sino-nasal outcome test (SNOT-22) is a patient-reported outcome measure for chronic rhinosinusitis (CRS), assessing treatment response after 6 months of biologic uses in patients with severe CRS. We investigated score changes in each domain of SNOT-22 with biologics in patients with severe asthma.

Methods

A total of 229 patients with severe asthma and nasal symptoms were enrolled from a prospective, observational, multicenter cohort study. After 6 months of treatment with biologics or conventional GINA Step 4-5 management, SNOT-22 changes were evaluated by analyzing total and rhinological, extranasal rhinological, ear/facial, psychological, and sleep domain scores.

Results

The adjusted odds ratio (OR) of being a responder was significantly higher for dupil

SUBMITTER: Shim JS 

PROVIDER: S-EPMC12683743 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature